logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5758.produswest2
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.5758.produswest2
Showing 1 - 20 of 58 Items
Showing 1 - 20 of 58 Items
Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.
  • Current Page (20)
  • CSV
  • BibTeX
  • EndNote
  • All Results (58)
  • CSV
  • BibTeX
  • EndNote
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Decentralised hepatitis C management: A simplified, integrated model of care in a primary health centre in Pakistan, August 2022-June 2023

Mazzilli S, Aslam MK, Ahmed M, Wailly Y, Miazek M,  et al.
2025-11-27 • Journal of Viral Hepatitis
2025-11-27 • Journal of Viral Hepatitis

Pakistan has the world's highest hepatitis C virus (HCV) prevalence, yet access to HCV care remains limited. In collaboration with the Ministry of Health Sindh, Médecins Sans Frontièr...

Journal Article
|
Research
Journal Article
|
Research
Conference Material
|
Poster
Journal Article
|
Research
Journal Article
|
Review
Conference Material
|
Slide Presentation
Conference Material
|
Slide Presentation
Conference Material
|
Video

Antibiogo as an innovative solution to detect antimicrobial resistance: from an operational need to a CE-marked diagnostic test available for low-income and middle-income countries

Malou N
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
Conference Material
|
Video

Improving treatment of multidrug-resistant tuberculosis: Results of the endTB randomised clinical trial

Guglielmetti L
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
Conference Material
|
Abstract
Journal Article
|
Letter

Reduced critical concentration might not have improved MGIT-based DST’s sensitivity to rifampicin

Journal Article
|
Research
Journal Article
|
Protocol
Journal Article
|
Commentary
Conference Material
|
Slide Presentation
Technical Report
|
Evidence Brief
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Short Report

Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Ali MH,  et al.
2025-07-16 • Lancet Respiratory Medicine
2025-07-16 • Lancet Respiratory Medicine

Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A,  et al.
2025-01-29 • New England Journal of Medicine
2025-01-29 • New England Journal of Medicine

BACKGROUND

For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs ...

Increased access and attention to toxicity: lessons learnt from the first cohort of 6-month drug resistant tuberculosis regimens in Gujranwala, Pakistan

Muhammad S, Sannino L, Ahumuza V, Fatima H, Imtiaz S,  et al.
2024-11-08 • MSF Scientific Days Asia 2024
2024-11-08 • MSF Scientific Days Asia 2024

Usability and acceptability of self-testing for hepatitis C virus exposure in a high-prevalence urban informal settlement in Karachi, Pakistan

Mazzilli S, Aslam MK, Akhtar J, Miazek M, Wailly Y,  et al.
2024-09-27 • BMC Infectious Diseases
2024-09-27 • BMC Infectious Diseases

BACKGROUND

Hepatitis C virus (HCV) antibody self-testing (HCVST) may help expand screening access and support HCV elimination efforts. Despite potential benefit...

Assessing the impact of climate change on health in South Asia

Srivastava B, Zaidi N, Mantoo F
2024-08-22 • Acta Scientific Clinical Case Reports
2024-08-22 • Acta Scientific Clinical Case Reports

South Asia emerges as one of the most susceptible regions to a plethora of direct and indirect repercussions stemming from climate change. These include, but are not limited to, the r...

Improving treatment of multidrug-resistant tuberculosis: Results of the endTB randomised clinical trial

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Lachenal N,  et al.
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024

Antibiogo as an innovative solution to detect antimicrobial resistance: from an operational need to a CE-marked diagnostic test available for low-income and middle-income countries

Rapoud D, Cramer E, Al Asmar M, Sagara F, Ndiaye B,  et al.
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024

Improving treatment of multidrug-resistant tuberculosis: Results of the endTB randomised clinical trial

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Lachenal N,  et al.
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
INTRODUCTION
Tuberculosis (TB) is a major public health challenge encountered across many Médecins Sans Frontières (MSF) fields. Management of drug-resistant TB is an operational pri...
Rupasinghe P, 
Ashraf A, 
Barreda N, 
Parveen S, 
Zubair M, 
et al.
2024-05-02 • Antimicrobial Agents and Chemotherapy
2024-05-02 • Antimicrobial Agents and Chemotherapy

Nine-month, all-oral regimens for rifampin-resistant tuberculosis

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Abubakirov A,  et al.
2024-01-29 • medRxiv
2024-01-29 • medRxiv

BACKGROUND

Aft...

Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial

Patil SB, Tamirat M, Khazhidinov K, Ardizzoni E, Atger M,  et al.
2023-11-30 • Trials
2023-11-30 • Trials
BACKGROUND
Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yi...

Misinformation in humanitarian programmes: Lessons from the MSF Listen experience

Leyland J, Tiller S, Bhattacharya B
2023-11-23 • Journal of Humanitarian Affairs
2023-11-23 • Journal of Humanitarian Affairs
While health misinformation is important to address in humanitarian settings, over-focusing on it can obfuscate a more holistic understanding of a community’s needs in a crisis. Through ...

endTB Clinical Trial: Design, efficacy, safety & linezolid dose-reduction randomization results

endTB Study Group
2023-11-15 • The Union World Conference on Lung Health 2023
2023-11-15 • The Union World Conference on Lung Health 2023

High-quality evidence on new, all-oral, shortened MDR-TB regimens

endTB Study Group
2023-11-15
2023-11-15
Each year there are approximately 500,000 new cases of multidrug-resistant tuberculosis (MDR-TB) worldwide, but only a tiny fraction is successfully treated. The endTB trial, led by Méde...

Prevalence and risk factors for hepatitis C virus infection in an informal settlement in Karachi, Pakistan

Alam R, Aslam K, Ahmed M, Isaakidis P
2023-09-20 • PLOS Global Public Health
2023-09-20 • PLOS Global Public Health
The burden of hepatitis C virus (HCV) infection in Pakistan is amongst the highest in the world. People living in slums are likely to be at high risk of infection. Here, we describe the ...

Four-month high-dose rifampicin regimens for pulmonary tuberculosis

Jindani A, Atwine D, Grint D, Bah B, Adams J,  et al.
2023-09-01 • NEJM Evidence
2023-09-01 • NEJM Evidence
BACKGROUND
Shorter but effective tuberculosis treatment regimens would be of value to the tuberculosis treatment community. High-dose rifampicin has been associated with more rapid a...

Culture conversion at six months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis

Seung KJ, Khan PY, Franke MF, Ahmed SM, Aiylchiev S,  et al.
2019-11-02 • Clinical Infectious Diseases
2019-11-02 • Clinical Infectious Diseases
Delamanid should be effective against highly resistant strains of Mycobacterium tuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observation...